Top

Pediatric Drugs

Published in:

01-05-2001 | Therapy In Practice

Multiple Sclerosis In Childhood and Adolescence

Clinical Features and Management

Authors: Orit Pinhas-Hamiel, Ida Sarova-Pinhas, Dr Anat Achiron

Published in: Pediatric Drugs | Issue 5/2001

Abstract

The presentation of multiple sclerosis (MS) in childhood has traditionally been thought to be rare. However, more paediatric cases are now being reported, as a result of progress in diagnostic techniques with the use of sensitive imaging modalities of the brain and spinal cord.

Management from an early age and the availability of new treatment options have changed the outcome of paediatric MS. Drugs currently available for treatment, such as β-interferons, copolymer-1 and intravenous immunoglobulin G, have been found to reduce relapse rate, disease severity and progression to disability in adults, but have not been investigated in children and adolescents.

The overall outcome of MS in children is apparently no worse than in adults and the disease may even be less aggressive in children. In juvenile MS, disease progression does not appear to be related to age of onset, severity of neurological involvement or mono/polysymptomatic involvement at presentation.

The potential to treat MS has significantly changed the prognosis. Early diagnosis is important, as early treatment can prevent or delay the development of disability.

Pinhas-Hamiel O, Barak Y, Siev-Ner I, et al. Juvenile multiple sclerosis: clinical features and prognostic characteristics. J Pediatr 1998; 132: 735–7PubMedCrossRef

Ghezzi A, Deplano V, Faroni J, et al. Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler 1997; 3: 43–6PubMedCrossRef

Duquette P, Murray TJ, Pleines J, et al. Multiple sclerosis in childhood: clinical profile in 125 patients. J Pediatr 1987; 111: 359–63PubMedCrossRef

Hanefeld F, Bauer HJ, Christen HJ, et al. Multiple sclerosis in childhood: report of 15 cases. Brain Dev 1991; 13: 410–6PubMedCrossRef

Sindern E, Haas J, Stark E, et al. Early onset MS under the age of 16: clinical and paraclinical features. Acta Neurol Scand 1992; 86: 280–4PubMedCrossRef

Shaw CM, Alvord EC. Multiple sclerosis beginning in infancy. J Child Neurol 1987; 2: 252–6PubMedCrossRef

Vergani MI, Reimao R, Silva AM, et al. Multiple sclerosis with early childhood onset: a case report. Arq Neuropsiquiatr 1988; 46: 195–7PubMedCrossRef

Ruggieri M, Polizzi A, Pavone L, et al. Multiple sclerosis in children under 6 years of age. Neurology 1999; 53: 478–84PubMedCrossRef

Sanchez-Calderon M, de Santos T, Martin S, et al. Multiple sclerosis in childhood: our experience and a review of literature. Rev Neurol 1998; 27: 237–41PubMed

10.

Kohler B, Tzonos T, Gustorf R, et al. Bilateral cysts of the brain: an unusual manifestation of multiple sclerosis in childhood. Klin Paediatr 1980; 192: 275–80CrossRef

11.

Bye AM, Kendall B, Wilson J. Multiple sclerosis in childhood: a new look. Dev Med Child Neurol 1985; 27: 215–22PubMedCrossRef

12.

Wu CY, Huang SC. Multiple sclerosis in children: report of two cases. Chang Keng I Hsueh Tsa Chih 1995; 18: 285–91PubMed

13.

Mattyus A, Veres E. Multiple sclerosis in childhood: long term katamnestic investigations. Acta Paediatr Hung 1985; 26: 193–204PubMed

14.

Imai M, Tanaka M, Hamano S, et al. Childhood multiple sclerosis and allied demyelinative diseases. No To Hattatsu 1999; 31:44–7PubMed

15.

Rizzo JF, Lesseil S. Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study. Neurology 1988; 38: 185–90PubMedCrossRef

16.

Soderstrom M, Ya-Ping J, Hillert J, et al. Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 1998; 50: 708–14PubMedCrossRef

17.

Ghezzi A, Martinelli V, Torri V, et al. Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol 1999; 246: 770–5PubMedCrossRef

18.

Miyazaki I. Visual functions of optic neuritis in children caused by demyelinating disease. Nippon Ganka Gakkai Zasshi 1991; 95: 995–1003PubMed

19.

Haller P, Patzold U. Optic neuritis in childhood. Fortschr Neurol Psychiatr Grenzgeb 1979; 47: 209–16PubMed

20.

Kriss A, Francis DA, Cuendet F, et al. Recovery after optic neuritis in childhood. J Neurol Neurosurg Psychiatry 1988; 51: 1253–8PubMedCrossRef

21.

Riikonen R, Donner M, Erkkila H. Optic neuritis in children and its relationship to multiple sclerosis: a clinical study of 21 children. Dev Med Child Neurol 1988; 30: 349–59PubMedCrossRef

22.

Arii J, Sugita K, Takanashi J, et al. Two early-childhood cases of optic neuritis. No To Hattatsu 1996; 28: 336–40PubMed

23.

Lucchinetti CF, Kiers L, O’Duffy A, et al. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology 1997; 49: 1413–8PubMedCrossRef

24.

Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227–31PubMedCrossRef

25.

Miller DH, Robb SA, Ormerod IE, et al. Magnetic resonance imaging of inflammatory and demyelinating white-matter diseases of childhood. Dev Med Child Neurol 1990; 32: 97–107PubMedCrossRef

26.

Scaioli V, Rumi V, Cimino C, et al. Childhood multiple sclerosis (MS): multimodal evoked potentials (EP) and magnetic resonance imaging (MRI) comparative study. Neuropediatrics 1991; 22: 15–23PubMedCrossRef

27.

Ebner F, Millner MM, Justich E. Multiple sclerosis in children: value of serial MR studies to monitor patients. Am J Neuro-radiol 1990; 11: 1023–7

28.

Kil K, Zang YC, Yang D, et al. T cell responses to myelin basic protein in patients with spinal cord injury and multiple sclerosis. J Neuroimmunol 1999; 98: 201–7PubMedCrossRef

29.

Ristori G, Montesperelli C, Gasperini C, et al. T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosis. J Neuroimmunol 1999; 99: 91–6PubMedCrossRef

30.

Ichikawa M, Koh CS, Inoue A, et al. Anti-IL-12 antibody prevents the development and progression of multiple sclerosis-like relapsing-remitting demyelinating disease in NOD mice induced with myelin oligodendrocyte glycoprotein peptide. J Neuroimmunol 2000; 102: 56–66PubMedCrossRef

31.

Windhagen A, Anderson DE, Carrizosa A, et al. Cytokine secretion of myelin basic protein reactive T cells in patients with multiple sclerosis. J Neuroimmunol 1998; 91: 1–9PubMedCrossRef

32.

Beck RW, Cleary PA, Anderson Jr MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326: 581–8PubMedCrossRef

33.

Filippi M, Rovaris M, Capra R, et al. Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology. J Neurol Neurosurg Psychiatry 1999; 67: 386–9PubMedCrossRef

34.

Prat A, Al-Asmi A, Duquette P, et al. Lymphocyte migration and multiple sclerosis: relation with disease course and therapy. Ann Neurol 1999; 46: 253–6PubMedCrossRef

35.

Noseworthy JH, Gold R, Hartung HP. Treatment of multiple sclerosis: recent trials and future perspectives. Curr Opin Neurol 1999; 12: 279–93PubMedCrossRef

36.

Adams AB, Tyor WR, Holden KR. Interferon beta-1b and childhood multiple sclerosis. Pediatr Neurol 1999; 21: 481–3PubMedCrossRef

37.

Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997; 349: 589–93PubMedCrossRef

38.

Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology 1998; 50: 398–402PubMedCrossRef

39.

Noseworthy JH, O’Brien PC, van Engelen BG, et al. Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler’s virus model to a randomised, double-blind, placebo-controlled clinical trial. J Neurol Neurosurg Psychiatry 1994; 57 Suppl.: 11–4PubMedCrossRef

40.

Sorensen P, Wanscher B, Jensen C, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50: 1273–81PubMedCrossRef

41.

Weinstock-Guttman B, Jacobs LD. What is new in the treatment of multiple sclerosis? Drugs 2000; 59: 401–10PubMedCrossRef

42.

Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43: 910–8PubMedCrossRef

43.

Gonsette RE. Mitoxantrone immunotherapy in multiple sclerosis. Mult Scler 1996; 1: 329–32PubMed

44.

Takahashi I, Sawaishi Y, Takeda O, et al. Childhood multiple sclerosis treated with plasmapheresis. Pediatr Neurol 1997; 17: 83–7PubMedCrossRef

45.

Zhang I, Raus J. T cell vaccination in multiple sclerosis. Mult Scler 1996; 1:353–6PubMed

46.

Hermans G, Denzer U, Lohse A, et al. Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination. J Autoimmun 1999; 13: 233–46PubMedCrossRef

47.

Phadke JG. Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain 1990; 113: 1597–628PubMedCrossRef

48.

Cole GF, Stuart CA. A long perspective on childhood multiple sclerosis. Dev Med Child Neurol 1995; 37: 661–6PubMedCrossRef

Title: Multiple Sclerosis In Childhood and Adolescence
Clinical Features and Management
Authors: Orit Pinhas-Hamiel
Ida Sarova-Pinhas
Dr Anat Achiron
Publication date: 01-05-2001
Publisher: Springer International Publishing
Published in: Pediatric Drugs / Issue 5/2001
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI: https://doi.org/10.2165/00128072-200103050-00002

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Multiple Sclerosis In Childhood and Adolescence

Clinical Features and Management

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2001

Tourette Syndrome

Fluoroquinolones in Paediatrics

Pharmacological Management of Pain and Anxiety During Emergency Procedures in Children

Treatment of Typical Absence Seizures and Related Epileptic Syndromes

Role of Rural School Nurses in Asthma Management